World scientific leaders gather in Espoo to accelerate development of bioactive paper
New methods are being developed in Finland, under VTT's direction, for the economical mass production of bioactive paper products, among others based on printing technology. The development is accelerated by organizing a joint conference with Canada's SENTINEL Bioactive Paper Network. The objective of both networks is to develop completely new types of products which e.g. detect and deactivate pathogens like salmonella and SARS.
The cooperation between the Finnish and Canadian networks will be promoted in the conference, which runs from June 24-26, 2008 in Espoo. Nearly 40 representatives of SENTINEL Bioactive Paper Network are joining with the respective amount of Finnish network representatives. The focus of the conference is to find solutions to some of the technical challenges that still exist and on accelerating the development of commercial applications.
SENTINEL's scientific director, and the professor of chemical engineering in Canada Research Chair in Interfacial Technologies and at McMaster University Robert Pelton mentions that one possible application could be for instance a strip of paper which could immediately identify the presence of contaminates in drinking water.
According to Tomi Erho, Senior Rsearch Scientist at VTT, this conference marks an important milestone in developing new bioactive paper products. By joining the forces of a large group of highly skilled researchers and by sharing knowledge and skills, the research parties believe to progress faster towards their goal. Customers may have access to the first simple applications within five years.
Bioactive paper is a product that includes functionalities based on the selective reactions of biomolecules, such as enzymes or antibodies. The application possibilities are extensive and less expensive than products that are in the market today. They consist of e.g. indicators or sensors attached to filters, food product packaging or personal health diagnostics. In printed intelligence applications, the paper's competitiveness lies in the fact that it is biodegradable, which is important in terms of sustainable development.
Other news from the department science
![[Fe]-hydrogenase catalysis visualized using para-hydrogen-enhanced nuclear magnetic resonance spectroscopy](https://img.chemie.de/Portal/News/675fd46b9b54f_sBuG8s4sS.png?tr=w-712,h-534,cm-extract,x-0,y-16:n-xl)
These products might interest you
Mini-UniPrep™ by Cytiva
Improved HPLC sample preparation
Save 66% sample preparation time and reduce costs by 40%
FIBRETHERM by C. Gerhardt
Automatic Fibre Extraction for Feed Analysis
FIBRETHERM from C. Gerhardt: Efficient – Precise – Method-Compliant
Hahnemühle LifeScience Catalogue Industry & Laboratory by Hahnemühle
Wide variety of Filter Papers for all Laboratory and Industrial Applications
Filtration Solutions in the Life Sciences, Chemical and Pharmaceutical Sectors
VICI Jour Katalog 15INT by VICI
The VICI Jour Catalog - Accessories for (U)HPLC and Liquid Handling
Capillaries, Tubing, Fittings, Filters, Safety-Products, Tools and much more
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
